<https://helda.helsinki.fi>

Inhibition of TGF beta 1 and TGF beta 3 promotes hematopoiesis in Fanconi anemia

Rodriguez, Alfredo

2021-01

Rodriguez , A , Yang , C , Furutani , E , Teresa , B G D , Velazquez , M , Filiatrault , J , Sambel , L A , Phan , T , Flores-Guzman , P , Sanchez , S , Orozco , A M , Mayani , H , Bolukbasi , O V , Färkkilä , A , Epperly , M , Greenberger , J , Shimamura , A , Frias , S , Grompe , M , Parmar , K & D'Andrea , A D 2021 , ' Inhibition of TGF beta 1 and TGF beta 3 promotes hematopoiesis in Fanconi anemia ' , Experimental Hematology , vol. 93 , pp. 70-U53 . <https://doi.org/10.1016/j.exphem.2020.11.002>

<http://hdl.handle.net/10138/339083>

<https://doi.org/10.1016/j.exphem.2020.11.002>

cc_by_nc_nd

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Inhibition of TGF β 1 and TGF β 3 promotes hematopoiesis in Fanconi anemia

Alfredo Rodríguez^{a,b}, Chunyu Yang^a, Elissa Furutani^c, Benilde García de Teresa^b, Martha Velazquez^a, Jessica Filiatrault^a, Larissa A Sambel^a, Tin Phan^a, Patricia Flores-Guzmán^d, Silvia Sánchez^b, Angélica Monsiváis Orozco^b, Héctor Mayani^d, Ozge V. Bolukbasi^c, Anniina Färkkilä^{a,e}, Michael Epperly^f, Joel Greenberger^f, Akiko Shimamura^c, Sara Frías^{b,g}, Markus Grompe^h, Kalindi Parmar^a, and Alan D. D'Andrea^a

- a) Department of Radiation Oncology and Center for DNA Damage and Repair, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
- b) Instituto Nacional de Pediatría, Mexico City 04530, Mexico
- c) Dana Farber and Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA 02115, USA
- d) Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico
- e) Research Program in Systems Oncology & Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland
- f) Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
- g) Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
- h) Oregon Health and Science University, Portland, OR, 97239, USA

Keywords: TGF β , Fanconi Anemia, Bone Marrow Failure

Running Title: TGF β inhibition promotes HSPC survival in Fanconi anemia

ABSTRACT

Fanconi anemia (FA) is a chromosome instability syndrome with congenital abnormalities, cancer predisposition and bone marrow failure (BMF). While hematopoietic stem and progenitor cell (HSPC) transplantation is the recommended therapy, new therapies are needed for FA patients without suitable donors. BMF in FA is caused, at least in part, by a hyperactive growth suppressive TGF β pathway, regulated by the TGF β 1, TGF β 2, and TGF β 3 ligands. Accordingly, the TGF β pathway is an attractive therapeutic target for FA. While inhibition of TGF β 1 and TGF β 3 promotes blood cell expansion, inhibition of TGF β 2 is known to suppress hematopoiesis. Here, we report the effects of AVID200, a potent TGF β 1 and TGF β 3 specific inhibitor, on FA hematopoiesis. AVID200 promoted the survival of murine FA HSPCs *in vitro*. AVID200 also promoted *in vitro* the survival of human HSPCs from patients with FA, with the strongest effect in patients progressing to severe aplastic anemia or myelodysplastic syndrome (MDS). Previous studies have indicated that the toxic upregulation of the Non-Homologous End Joining (NHEJ) pathway accounts, at least in part, for the poor growth of FA HSPCs. AVID200 downregulated the expression of NHEJ related genes and reduced DNA damage in primary FA HSPCs *in vitro* and in *in vivo* models. Collectively, AVID200 shows activity in FA mouse and human preclinical models. AVID200 may therefore provide a therapeutic approach to improving BMF in FA.

INTRODUCTION

Fanconi anemia (FA) is a chromosome instability syndrome characterized by congenital malformations, cancer predisposition, and childhood onset of bone marrow failure (BMF) [1-3]. FA is the most common inherited BMF syndrome, and BMF occurs due to a defect in the maintenance of the hematopoietic stem and progenitor cell (HSPC) pool [4, 5]. HSPC pool attrition in FA patients underlies the development of aplastic anemia (AA) as well as the strong predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) [1, 6, 7].

FA is caused by inherited bi-allelic mutations in any of the twenty-three FA genes (*FANCA* to *FANCW*) [7-9] whose protein products coordinately repair DNA interstrand crosslinks (ICLs). ICLs interfere with the progression of replication forks during S phase of the cell cycle [2]. ICLs are detected by the FA core complex, and they are unhooked by endonucleases associated with the FANCD2/I complex. The resulting double strand break (DSB) is ultimately repaired by the downstream homologous recombination repair (HRR) machinery [10, 11]. The final step in DSB repair is coordinated by downstream FA gene products, including FANCS/BRCA1 and FANCD1/BRCA2 [12].

A defective FA pathway has been linked to the accumulation of DNA damage and to the hyperactivation of growth suppressive pathways in the HSPC pool. On the one hand, DNA damage activates the p53 pathway which hyperactivates p21 and arrests FA HSPCs in the G1 phase of the cell cycle [4]. On the other hand, a hyperactive TGF β pathway

contributes to the BMF in FA by promoting the toxic upregulation of non-homologous end-joining (NHEJ), leading to the accumulation of misrepaired DNA damage, unresolved chromosome radials, and HSPC growth suppression [13]. TGF β pathway inhibitors downregulate the NHEJ pathway genes and upregulate the high-fidelity HRR genes, thus promoting the survival and proliferation of mouse and human FA HSPCs both in *in vitro* and *in vivo* models [13].

Three different TGF β ligands - namely, TGF β 1, TGF β 2, and TGF β 3, regulate the TGF β pathway [14]. The three TGF β isoforms remain in the extracellular space as inactive TGF β dimers until their cleavage and activation by the matrix metalloproteinases, MMP2 and MMP9, or by integrin-mediated mechanisms [15].

The TGF β pathway is dysregulated in several human diseases, including idiopathic pulmonary fibrosis, [16, 17], myelofibrosis [18, 19], MDS [20], AML [21] and other types of cancers [22]. Drugs have been developed for targeting components of this pathway, including small-molecule inhibitors, monoclonal antibodies, antisense oligonucleotides, and vaccines, all of which have been analyzed in preclinical models. TGF β pathway inhibitors are effective in eliminating cancer stem cells in mouse models of glioblastoma [23] and chronic myeloid leukemia [24] and can block metastasis in mouse breast cancer models [25].

TGF β inhibitors have moved into clinical trials, particularly for the treatment of fibrosis and cancer. These agents include the monoclonal antibody Fresolimumab, the antisense oligonucleotide Trabedersen [26], the small molecule inhibitor Galunisertib developed by

Eli Lilly against TGF β RI [27, 28], TGF β ligand trap [29] and Losartan, a pre-existing antihypertensive drug that inhibits the angiotensin type II receptor but also blocks TGF β signaling [30]. More recently, TGF β pathway inhibitors have been shown to boost immune-response in immunotherapy trials [31, 32]. Such is the case for M7824, a bifunctional fusion protein composed of a monoclonal antibody against programmed death ligand 1 (PD-L1) fused to a TGF- β trap [33].

Although inhibitors targeting the three types of TGF β ligands or the TGF β receptors have been shown to promote hematopoiesis (e.g. SD208, 1D11, Galunisertib) [13, 34], inhibition of the TGF β 2 ligand is less desirable since its inhibition induces cardiotoxicity and metastasis [35]. Also, TGF β 2 positively regulates hematopoiesis [36], and its inhibition could in principle accelerate BMF in FA.

In the current study, we employed preclinical models to evaluate the activity of AVID200, a TGF β ligand trap, on murine and human FA HSPCs. AVID200, constructed by fusing the TGF β R ectodomain to a IgG Fc region, is a potent TGF β trap, with 1000 times more potency against TGF β 1 and TGF β 3 and minimal activity against TGF β 2 [37]. AVID200 has been shown to be an efficient TGF β pathway inhibitor in preclinical models of Shwachman-Diamond syndrome that is also characterized by BMF [38]. Bone marrow plasma from FA patients contained **reduced levels of active TGF β 1 ligand**, significantly reduced levels of active TGF β 2 ligand and higher levels of active TGF β 3 ligand, compared to healthy controls. *In vitro* testing of the response to AVID200 in HSPC cells, derived from FA patients at different stages of the disease, showed that AVID200

promotes hematopoietic clonogenic growth in primary FA samples. Additional experiments using HSPCs from FA mouse models and FA patient-derived lymphoblastoid cell lines demonstrated that mechanistically AVID200 suppresses the toxic overexpression of the NHEJ transcriptional program and promotes efficient DNA repair.

METHODS

Isolation of mouse HSPCs and LT-HSC

Bone marrow cells were harvested from tibia and femurs of mice by gentle flushing with HBSS++ buffer [Hanks balanced salt solution (10-547F, Lonza) + HEPES (BP299-100, Fisher Scientific) + Fetal bovine serum (F2442, Sigma) + penicillin-streptomycin (15140-122, GIBCO)]. Samples were filtered through a 70 μ M filter to obtain a single cell suspension and Lin⁻ enrichment was performed with lineage negative selection using the lineage cell depletion kit (130-090-858, Miltenyi). For isolation of LSK cells and LT-HSCs, Lin⁻ cells were incubated with biotin-labeled lineage antibody cocktail from BD containing a mixture of antibodies against CD3, CD11b, CD19, B220, Gr-1 and Ter119 (51-09082J, BD Pharmingen), followed by staining with streptavidin-PE secondary antibody (554061, BD). LSK cells were identified as Lin-Sca-1+c-kit+ using PE-Cy7-Sca (Clone D7, 558162, BD Biosciences) and APC-c-kit (Clone ACK2, 135108, BD Biosciences) antibodies; whereas LT-HSCs were recognized by being LSK and CD150+CD48- using PE-Cy7-Sca (Clone D7, 558162, BD Biosciences), APC-c-kit (Clone ACK2, 135108, BD Biosciences), Pacific Blue-CD150 (Clone TC15-12F12.2, 115924, Biolegend) and APC-Cy7-CD48

(Clone HM48-1, 47-0481-82, e-Bioscience). Cells were sorted using a BD FACSAria cell sorter.

Western blotting for detection of phospho-SMAD2/3

Isolated Lin⁻ cells were expanded during 24 h in serum-free medium StemSpan SFEM (09600, StemCell Technologies) containing 1% penicillin/streptomycin (15140-122, GIBCO), 2% L-glutamine (25030-081 GIBCO), 100 ng/ml TPO (315-14-10UG, Peprotech) and 100 ng/ml SCF (250-03-10UG, Peprotech). Cells were exposed during 2 h to TGFβ1 (5 ng/ml), TGFβ2 (5 ng/ml) or TGFβ3 (5 ng/ml) along with AVID200 (25 ng/ml). Whole cell lysates were prepared using RIPA cell lysis buffer (9803, Cell Signaling) and 1 mM PMSF (8553s, Cell Signaling) and western blots were performed using the SMAD2/3 (86855, Cell Signaling), phospho-SMAD2 (ab3849, Millipore), phospho-SMAD2/3 (8828s, Cell Signaling) and β-actin (3700s, Cell Signaling) antibodies. A representative blot is shown.

Phosphoflow for analysis of phospho-SMAD2/3

Mouse Lin⁻ cells were exposed for 30 min to 5 ng/ml of mouse recombinant TGFβ1 (7666-MB-005/CF, R&D Biosystems) and 0.2 ng/ml of AVID200 (Forbuis) or 1D11 (10 μg/mL) for 1 h. Mouse LSK cells were cultured for 24 h in presence of 0.2 ng/ml of AVID200 (Forbuis). After culture Lin⁻ and LSK cells were gently fixed with pre-warmed BD Phosflow Lyse/Fix Buffer 1x (558049, BD Bioscience) and incubated for 10 min at 37°C, washed with BD PermWash Buffer (51-2091KZ, BD Bioscience), permeabilized while vortexing by slowly adding cold BD PermBuffer III (558050, BD Bioscience) and incubated 30 min

on ice. Cells were washed with BD PermWash buffer and incubated with PE mouse anti-Smad2/3 antibody (562586, BD Bioscience) during 30 min at RT. Cells were washed with BD PermWash buffer and run in a CytoFLEX flow cytometer (Beckman Coulter). Data were analyzed using FLOWJO (FLOWJO, LLC) version 10.4.2.

Survival assays with mouse bone marrow cells

For clonogenic assays, 20,000 Lin⁻ cells per condition (in triplicate) and 2000 sorted LSK cells per condition (in triplicate) were plated in Methocult GF M3434 methylcellulose (03444, Stem Cell Technologies) and cultured for 7 days. The TGF β inhibitors such as AVID200 (Forbius), SD208 (S7071, Sigma-Aldrich) and 1D11 (Genzyme) were added in graded concentrations in the cultures. For acetaldehyde treatments, bone marrow cells were exposed to increasing doses of acetaldehyde (00070-100ML, Sigma-Aldrich) for 4 h, washed and then cultured in Methocult GF M3434 methylcellulose. The hematopoietic colonies were scored after 7 days of culture at 37 °C and 5% CO₂.

For proliferation assays, sorted LSK cells were cultured in serum-free medium StemSpan SFEM (09600, StemCell Technologies) containing 1% penicillin/streptomycin (15140-122, GIBCO), 2% L-glutamine (25030-081 GIBCO), 100 ng/ml TPO (315-14-10UG, Peprotech) and 100 ng/ml SCF (250-03-10UG, Peprotech). After 48 h in culture, DNA damage was assessed by immunofluorescence staining the cells to detect γ H2AX foci formation (2577s, Cell Signaling) as described [13].

Viral transduction of CD34⁺ cells

Isolated human CD34⁺ cells were cultured in StemSpan SFEMII (09655, Stem Cell Technologies,) with 100ng/ml of all recombinant human cytokines SCF (300-07, Peprotech), TPO (300-18, Peprotech), Flt3 (300-19, Peprotech) and IL-6 (200-06, Peprotech) at a density of 1-2 million cells/ml in non-tissue culture (non-TC) treated plates for 36 hours. After initial culture, cells were plated in non-TC treated 96 well plates with a density of $1-2 \times 10^5$ cells in 100-150 μ l of new media with 8 μ g/ml polybrene (TR-1003-G, Sigma) and shRNA producing lentivirus targeting human *FANCD2*. A MOI of 50 was used for the scrambled shRNA and a MOI of 100 was used for the targeted shRNAs. Plates were spun down at 2300 rpm for 30 minutes at RT after addition of the viral prep. New media was added after 12-16 hours of incubation. Selection media with 1 μ g/ml puromycin (MIR 5940, MirusBio) was added to cultures 12-24 hours after viral infection. Puromycin selection was applied during 72 hours. Puromycin resistant cells were used for assays with FA-like cells.

Human HSPC isolation and culture

Whole bone marrow was obtained from FA patients after informed consent of sample usage for research. Fresh healthy bone marrow samples were purchased from Lonza (1M-105, Lonza). Red blood cell lysis was performed by incubating the samples with Ammonium Chloride (07800, StemCell Technologies) for 10 min on ice followed by washing with PBS. After red blood cell lysis, Lin⁻ cells were enriched from mononuclear cells (MNCs) by negative selection using the EasySep kit (19056, StemCell Technologies), according to manufacturer's instructions.

Clonogenic potential of human HSPC was assessed in CFU assays by plating 3000 HSPCs per triplicate in human methylcellulose MethoCult H4434 Classic (04434, StemCell Technologies). Colonies were quantified and classified 14 days after culture. Pictures were taken with the STEMvision System (StemCell Technologies). Proliferation potential of human HSCPs was assessed by culturing human Lin⁻ cells in 96 well plates in Serum-Free Expansion Medium StemSpan SFEM (09600, StemCell Technologies) supplemented with recombinant human hematopoietic cytokines: TPO (100 ng/ml) (AF-300-18, Peprotech), Flt-3 (100 ng/ml) (AF-300-19, Peprotech), SCF (100 ng/ml) (AF-300-07, Peprotech) and IL-6 (20 ng/ml) (AF-200-06, Peprotech) for 7 days.

Cytokines quantification

Plasma was collected from human whole bone marrow blood and subjected to a bead-based Multiplex Immunoassay for detection of human cytokines TGFβ1, TGFβ2, TGFβ3 using the discovery assay of Eve Technologies (Eve Technologies Corporation, Canada). This multiplexing technology is based on color-coded antibody-coupled polystyrene beads. The bead analyzer Bio-Plex 200 (BIORAD) was used for detection and results were quantified according to a standard curve.

Immunofluorescence

Sorted LT-HSCs were cytopun into SuperFrost slides (12-550-15, Fisher Scientific) and fixed for 15 min in 4% paraformaldehyde (30525-89-4, Electron Microscopy Sciences) in PBS. Cells were then permeabilized in 0.2% Triton-X-100/PBS and incubated for 1 h in

blocking buffer (1% FCS/0.1% Triton-X-100/PBS). For γ H2AX staining, cells were incubated with rabbit anti-mouse phospho-histone H2A.X (Ser 139) antibody (2577s, Cell signaling) and incubated with a secondary antibody anti rabbit Alexa Fluor-488 (20E3, Cell Signaling) diluted 1:200 in 1% FCS/PBS and incubated in a humidified chamber overnight. The following day slides were washed three times for 5 min in PBS, counterstained and mounted with ProLong Gold antifade reagent with DAPI (P36931, Life Technologies). Images were taken with a Zeiss Imager fluorescent microscope. Slides were assessed for γ H2AX foci using Cell Profiler (Open cell image analysis software).

Quantitative real-time PCR array and targeted RNAseq

RNA was extracted from LSK cells using the micro RNA extraction kit (74034, QIAGEN) and from lymphoblast cell lines using the Mini RNA extraction kit (74134, QIAGEN) following the manufacturer's instructions. RNA quality was assessed using an Agilent Bioanalyzer and RNA Nano Chip in the Biopolymers Facility of Harvard Medical School.

For gene expression analysis of LSK cells, cDNA was synthesized using the RT² PreAMP cDNA synthesis kit (33045, QIAGEN), target sequences were amplified using the RT² PreAMP Pathway primer Mix (PBM-029Z, 30241, QIAGEN) and qPCR Master Mix was RT² SYBR® Green (330533, QIAGEN). Multiplex real-time PCR was performed with the Mouse DNA damage signaling pathway PCR array (PAMM-029ZA, QIAGEN) following manufacturer's instructions. PCR was performed in a QuantStudio 7 Flex real Time machine (Life Technologies). For the gene expression analysis in EUFA316 cells, a

QIAseq Targeted RNA panel targeted was designed (CRHS-10510Z-219-12, 333022, QIAGEN) following manufacturer's instructions. Index assignment was done using the QIAseq Targeted RNA 96-index I kit (333117, QIAGEN). Libraries were sequenced in a Illumina NextSeq 500 Mid Output flow cell and run in an Illumina NextSeq 500 sequencer in the Biopolymers Facility of Harvard Medical School.

Survival assays

For survival assays, EUFA316+EV and EUFA316+G cells were exposed to increasing doses of acetaldehyde during 4 h, washed and seeded at a density of 1×10^3 cells per well in 96-well plates. Cell viability was assessed after 5 days of culture using the Cell Titer-Glo® Luminescent Cell Viability Assay (G7573, Promega).

Chromosome aberration analysis

EUFA316+EV and EUFA316+G cell lines were pre-treated with 0.2 ng/ml of AVID200 (Forbuis) during 24 h and then exposed to MMC (20 ng/ml) during 48 h and harvested. Alternatively, the cell lines were pre-treated with 0.2 ng/ml of AVID200 (Forbuis) during 24 h, exposed for 4 h to acetaldehyde (2 mM), washed and allowed to recover during 48 h. Cells were harvested using KaryoMAX® Colcemid® Solution (15210-040, GIBCO) for 1 h, treated with hypotonic solution for 20 min and fixed with methanol: glacial acetic acid solution (3:1) (both from Fisher) solution. Samples were washed 3 times with methanol (A412-500, Fisher):acetic acid (A38S-500, Fisher) solution, cells were dropped into slides and stained with Giemsa staining solution (Fisher). Chromosome breaks and radial

figures were scored in 50 metaphases per condition using conventional cytogenetic criteria.

Karyotyping and FISH analysis of bone marrow and blood

BM blood samples were cultivated following standard cytogenetic procedures. Fluorescent in situ hybridization (FISH) was performed on fresh bone marrow samples using Vysis probes LSI 7q31 (D7S486) spectrum orange/ CEP7 spectrum green, LSI 1p36 spectrum orange/LSI 1q25 spectrum green, LSI BCL6 (ABR) Dual color (SG/SO) Break apart (all from Abbott Molecular). For G banding 25 metaphase spreads were analyzed per patient. A **cytogenetic** clone with chromosome gain was reported when the same chromosome gains were discovered in at least 2 cells, a **cytogenetic** clone with chromosome lost was reported when the same chromosome abnormality was found in at least three cells. For FISH 1000 cells were scored and the finding of >5% cells with the same abnormality was considered a **cytogenetic clone**. **Cytogenetic** clone definition and karyotype formulas were according to the **International System for Chromosome Nomenclature** (ISCN) 2016 guidelines.

Alkaline comet assay

Sorted LT-HSCs were mixed with low-melting-temperature agarose, plated on slides and incubated at 4°C overnight in lysis solution using the CometAssay kit (4250-050-K, Trevigen) and following manufacturers' instructions. Next day cells were subject to a current voltage of 12 V washed and stained with SybrGreen dye (S7567, Invitrogen). As a DNA damage positive control, some cells were exposed to 10 Gy of irradiation using a

^{137}Cs radiation source (model RS2000, Rad source) with a dose rate of 1 Gy min. Pictures were taken with a Zeiss Imager Z1 fluorescence microscope and olive-tail moment analysis was performed using the OpenComet plugin in Image J software.

Patients and Clinical correlations of CFU data

Data from FA patients were obtained from the clinical records of the Boston Children's Hospital and Instituto Nacional de Pediatría, Mexico. Absolute neutrophil count (ANC), Platelet count (PC), and Hemoglobin (Hb) levels were used for classifying the patients as having mild aplastic anemia if $\text{ANC} < 1,500/\text{mm}^3$, $\text{PC} 150,000\text{-}50,000/\text{mm}^3$ and $\text{Hb} \geq 8 \text{ g/dL}$; moderate aplastic anemia if $\text{ANC} < 1,000/\text{mm}^3$, $\text{PC} < 50,000/\text{mm}^3$ and $\text{Hb} < 8 \text{ g/dL}$; and severe aplastic anemia if $\text{ANC} < 500/\text{mm}^3$, $\text{PC} < 30,000/\text{mm}^3$ and $\text{Hb} < 8 \text{ g/dL}$.

Statistics

Normality was assessed using the D'Agostino-Pearson, Shapiro-Wilk and Kolmogorov Smirnov normality tests. 2-way ANOVA and Tukey's multiple comparisons test were used for detection of differences between experimental groups. $\text{TGF}\beta$ levels in bone marrow plasma were compared using unpaired t test with Welch correction. γH2AX and Olive tail moment were analyzed using the Kruskal-Wallis test. Colony counts in CFU assays were transformed to fold-change by dividing the average colonies in the AVID200 treated sample by the average in the untreated sample and correlated to clinical data presented in Table 1. CFU fold change in primary samples exposed to AVID200 were compared using Student's t-Test and Wilcoxon matched-pairs signed rank test. Graphpad Prism 8 was used for all statistical analysis.

Study approval

Experimental procedures were approved by the Animal Care and Use Committee of the Dana Farber Cancer Institute. Written informed consent was received from participants prior to inclusion in the study.

RESULTS

TGF β Inhibition by AVID200 results in enhanced murine HSPC colony growth

We have previously shown that inhibition of TGF β by a neutralizing antibody rescues the growth defects in murine FA bone marrow (10). In the current work we tested the specificity of AVID200 for sparing the activity of TGF β 2. We confirmed that AVID200 reduces the activity of the TGF β 1 and TGF β 3 ligands but not TGF β 2 on murine progenitors and HSPCs, as determined by reduced SMAD2/3 phosphorylation in cells exposed *in vitro* to the three members of the TGF β ligand family (**Figure 1A and Supplementary Figure 1A-B**). We next compared the performance of AVID200 in promoting hematopoietic colony formation with respect to other known pharmacological inhibitors of TGF β pathway in murine FA bone marrow. Lineage negative (Lin⁻) bone marrow cells from WT and *Fancd2*^{-/-} mice were cultured in a methylcellulose medium in presence of either a small molecule inhibitor of TGF β Receptor I (**SD208**), a neutralizing antibody against TGF β ligands (1D11), or AVID200 (a TGF β 1 and TGF β 3 molecular trap), and clonogenic growth was determined (**Figure 1B and Supplementary Figure 1C**). All TGF β pathway inhibitors including AVID200 promoted the clonogenic growth of bone marrow progenitors from *Fancd2*^{-/-} mice (**Figure 1B**). Colony size was increased after AVID200 treatment. **Increased proliferation and increased colony size after AVID200 treatment was confirmed by solubilization of the hematopoietic colonies and quantification of cell numbers after the culture (Supplementary Figure 1D).**

TGF β inhibition by AVID200 rescues the clonogenic defects of primary FA-patient derived bone marrow

We next tested the effects of AVID200 on primary human cells. Using a lentivirus expressing a short-hairpin RNA (shRNA) against *FANCD2*, we generated FA-like HSPCs using cord blood CD34⁺ cells. Two different shRNAs against *FANCD2*, expressed in primary cord blood CD34⁺ cells, reduced the relative abundance of *FANCD2* transcript (**Supplementary Figure 2A**). As expected, primary human FA-like HSPCs exhibited reduced clonogenic potential, and AVID200 rescued these clonogenic growth defects in a dose dependent manner (**Figure 2A and Supplementary Figure 2B**). Similar to mouse CFU, the colony size was increased after AVID200 treatment. The increase in colony size and increased proliferation of FA-like cells after AVID200 treatment was confirmed by solubilization of the hematopoietic colonies and quantification of cell numbers after the culture (**Supplementary Figure 2C**).

The TGF β ligand family is composed of three members, TGF β 1, β 2, and β 3, which are secreted into the extracellular milieu as inactive homodimers that become active monomers once they are cleaved by specific extracellular metalloproteases or integrins [15]. Active TGF β monomers have the capacity to bind to the TGF β receptor I and to activate signal transduction pathways, culminating in changes in gene expression [22]. Overexpression of the TGF β pathway genes is evident in mouse and human FA bone marrow [13], however, elevated levels of TGF β ligands have not been reported in primary FA bone marrow-derived serum or plasma. Using an immunoassay, we observed an

imbalance in the levels of TGF β ligands in the plasma collected from the bone marrow of 12 FA patients. There was a **reduction in the level of active (free) TGF β 1**, a significant reduction in the level of active TGF β 2 and an increase in level of active TGF β 3 in bone marrow plasma of FA patients (**Figure 2B**). As TGF β 1 and TGF β 3 are growth suppressive for HSPCs, the significantly increased levels of active TGF β 3 in the FA BM plasma may activate the growth suppressive pathways accounting for BMF in FA patients. Reduced levels of active TGF β 2 may account for the ineffective stimulation of hematopoiesis in FA. The levels of total TGF β ligands have a distribution similar to the levels of active TGF β ligands, meaning increased TGF β 3, and reduced TGF β 1 and TGF β 2 in FA samples (**Supplementary Figure 2D**).

To determine whether specific inhibition of elevated TGF β 3 in FA bone marrow can rescue the bone marrow defects, we next assessed the effects of AVID200 in primary HSPCs from FA patients. Bone marrow Lin⁻ cells were cultured for seven days in the presence of growth factors, and cell proliferation was determined. AVID200 enhanced proliferation of HSPCs from 7 out of 9 FA samples. FA patients at different clinical stages of their disease were included in this study. As expected, only low numbers of HSPCs were obtained from FA patients with severe aplastic anemia (samples 10, 13, 17 and 21). Accordingly, only a single measurement (*sm*) of survival was possible for these patients (**Supplementary Figure 2E**). We next determined the clonogenic potential of primary Lin⁻ cells from 20 FA patients by culturing them in methylcellulose medium in the presence or absence of AVID200. An overall significant increase in total colony numbers was observed with AVID200 in most of the FA samples (**Figure 2C**). AVID200 increased also

the myeloid and erythroid clonogenic potential of the bone marrow from FA patients (**Figure 2C**). A representative photomicrograph shows the improved CFU-C capacity of FA samples cultured with AVID200 (**Figure 2D**). Response to AVID200 in the bone marrow of individual FA patients is presented in the supplementary Figures (**Supplementary Figure 2F, 2G and 2H**). Although the triplicate cultures were not possible from all the samples, a tendency of increased colony numbers was observed with AVID200 in the bone marrow from most of the FA patients. Importantly, the samples which did not exhibit an overall colony improvement, showed an improvement in either the myeloid or erythroid colony formation (**Supplementary Figure 2G and 2H**).

Clinical information from FA patients (**Table 1**) was used to derive correlations with AVID200 response. The samples from patients with advanced aplastic anemia displayed the highest fold change in response to AVID200, whereas patients with mild anemia showed only a modest response to AVID200 (**Figure 2E**). Interestingly, samples derived from patients with cytogenetic evidence of clonal **cytogenetic** abnormalities were among the best responders to AVID200 (**Figure 2F**). Collectively, inhibition of TGF β 1 and TGF β 3 by AVID200 promoted the clonogenic potential of primary bone marrow progenitors from FA patients.

TGF β inhibition by AVID200 rescues DNA repair defects of FA HSPCs

We have previously shown that TGF β pathway inhibitors downregulate error-prone NHEJ pathway gene expression and upregulate high-fidelity HRR gene expression [13]. We

therefore next asked whether specific inhibition of TGF β 1 and TGF β 3 will have similar consequences.

Since efficient DNA repair may improve the cellular survival, we challenged murine *Fancd2*^{-/-} Lin⁻ cells (**Figure 3A**) and *Fancg*^{-/-} Lin⁻ cells (**Supplementary Figure 3A**) by exposure to acetaldehyde, a DNA damaging agent to which FA cells are hypersensitive [39, 40]. As expected, the *in vitro* clonogenic potential of *Fancd2*^{-/-} and *Fancg*^{-/-} cells was reduced upon exposure to acetaldehyde, in contrast to WT cells (**Figure 3A and Supplementary Figure 3A**). Acetaldehyde hypersensitivity of *Fancd2*^{-/-} and *Fancg*^{-/-} cells was significantly rescued with AVID200 pretreatment. In addition, AVID200 rescued the acetaldehyde sensitivity of murine *Fancd2*^{-/-} HSPCs (Lin⁻Sca-1⁺c-Kit⁺, LSK cells) and improved their proliferation (**Supplementary Figure 3B**). AVID200 also reduced acetaldehyde-induced DNA damage in LSK cells from *Fancd2*^{-/-} mice as assessed by two assays, reduction in the amount of γ H2AX foci (**Figure 3B**) and reduction in the amount of BrdU foci (**Supplementary Figure 3C, 3D**), in this assay the thymidine analogue BrdU is incorporated into the DNA of cycling cells, and after induction of DNA damage the amount of single stranded DNA formation at not-rejoined DSBs can be quantified by using an antibody that only recognizes BrdU in single stranded DNA but not in double stranded DNA.

One of the best characterized mechanisms of action of the TGF β pathway is the regulation of gene expression through its downstream effectors [22], We therefore hypothesized that AVID200 rescues DNA damage and improves survival of FA cells by

modulating the gene expression profile of DNA repair genes. Murine *Fancd2*^{-/-} LSK cells were therefore exposed *in vitro* to AVID200, and changes in expression of a panel of genes involved in DNA repair and genome maintenance were evaluated by a multiplex real time-PCR assay. Remarkably, AVID200 induced a switch in the gene expression profile of *Fancd2*^{-/-} LSK cells (**Figure 3C**), resulting in downregulation of genes involved in NHEJ, namely, *Prkdc* (encoding for DNA-PK) and *Trp53bp1* (encoding for 53bp1) [41, 42]. These results suggest that AVID200 inhibits the expression of NHEJ genes, thus allowing the repair of DSBs by HR mechanisms without interference by NHEJ. Moreover, improved DNA repair capacity was predicted to reduce p53 pathway activation. Accordingly, the *Trp53* gene (encoding for p53) was also downregulated after AVID200 treatment, thereby reducing cell cycle checkpoint activation and allowing for enhanced cell proliferation.

Although, FA mice do not exhibit bone marrow failure spontaneously, BMF can be induced by exposure of mice to a physiological stress such as polyinosinic-polycytidylic acid (pl:pC). pl:pC is a potent inducer of the type 1 interferon response [43]. pl:pC activates the HSCs in FA mice and induces DNA damage resulting into BMF [43]. We therefore next asked whether physiological stress-induced DNA damage in HSCs can be reduced by AVID200. WT and *Fancd2*^{-/-} mice were exposed to pl:pC and AVID200, and DNA damage was assessed in LT-HSCs after 48 hrs (**Figure 3D left panel**) and after 30 days (**Figure 3D right panel**). As expected, pl:pC treatment caused DNA damage in LT-HSCs and increased levels of γ H2AX foci. AVID200 reduced the pl:pC-induced γ H2AX foci in LT-HSCs from both WT and *Fancd2*^{-/-} mice (**Figure 3D and 3E**), even after 30

days of continuous *in vivo* exposure. AVID200 also reduced the DNA damage in LT-HSCs, as assessed by the comet assay (**Supplementary Figure 3E and 3F**). Taken together, AVID200 reduces physiological stress-induced and acetaldehyde-induced DNA damage in HSCs from *Fancd2*^{-/-} mice.

TGFβ inhibition by AVID200 reduces chromosomal aberrations in FA lymphoblast cells

Although we observed an improvement in colony formation and survival in primary bone marrow from FA patients, the low number of primary HSPCs from FA patients limited extensive studies with AVID200. Therefore, we next assessed AVID200 in a human-lymphoblast FA cell line EUFA316+EV derived from a *FANCG* patient. As expected, the EUFA316+EV cells were more sensitive than its corrected counterpart (EUFA316+G cells) to increasing concentrations of acetaldehyde, and AVID200 rescued this sensitivity (**Figure 4A**). Acetaldehyde also induced chromosomal breaks and radials in EUFA316+EV cells. Remarkably, AVID200 significantly reduced the frequency of these chromosomal aberrations (**Supplementary Figure 4A**), AVID200 also significantly reduced the frequency of Mitomycin C (MMC)- induced chromosomal aberrations (**Figure 4B**).

TGFβ inhibition by AVID200 reduces NHEJ gene expression in FA lymphoblast cells

Using bone marrow HSPCs from *Fancd2*^{-/-} mouse model, we observed that AVID200 reduces the DNA damage and promotes cell survival, consistent with a reduction in the expression of NHEJ genes. We followed a similar approach and determined whether

AVID200 modifies the gene expression profile of the EUFA316 +EV cells using a custom RNAseq panel containing DNA repair gene targets.

Interestingly, the alternative error-prone DNA repair genes, *POLQ* [44] and *RAD52* [45], and NHEJ genes such as *TP53BP1* [41], were differentially expressed in the EUFA316+EV cell line, in comparison to the corrected EUFA316+G cells (**Figure 4C**). Changes in gene expression profile of the EUFA316+EV cells after 24 h of exposure to AVID200 were therefore assessed (**Figure 4D**). Of note, several genes switch their transcriptional expression in response to AVID200, depending on the presence or absence of a functional FA pathway. Specifically, in EUFA316+EV cells, *TERF1*, *RAD51*, *TOPBP1*, *ATRIP*, *LTBP2*, *MAD2L2* and *DDB2* were downregulated whereas *SIRT1*, *BLM*, *H2AFX*, and *DDB1* genes were upregulated after AVID200 exposure. The downregulation of expression of the *MAD2L2* gene, which encodes the REV7 protein, is noteworthy. REV7 protein, a subunit of the Shieldin complex, is critical for suppressing double strand break resection and promoting NHEJ activity [46]. Downregulation of *MAD2L2* promotes efficient HR repair, since the Shieldin complex becomes dismantled and NHEJ is mitigated [46-48]. As AVID200 rescues the chromosomal abnormalities including radial chromosomes, the reduced expression of genes encoding components of the NHEJ pathway, including *REV7*, may provide a mechanism by which AVID200 promotes efficient DNA repair and survival in FA cells.

DISCUSSION

FA pathway deficiency is known to result in a hyperactivation of the growth suppressive TGF β pathway [13]. TGF β is a master regulator of cellular proliferation during embryogenesis and in adult tissue homeostasis [49] and it contributes, at least in part, to the BMF of FA [13] and Shwachman-Diamond syndrome [38]. TGF β inhibits the growth of many cellular types, including epithelial, endothelial, hematopoietic, and immune cells. In the current study, we have shown that in contrast to healthy controls, the BM plasma from FA patients has increased concentrations of total and active TGF β 3 ligand, a potent inhibitor of HSPCs proliferation, and decreased concentrations of total and active TGF β 1 and TGF β 2 ligands, a positive regulator of HSPCs maintenance [36]. This imbalance of TGF β ligand isoforms contributes to the BMF in FA and offers a therapeutic strategy.

Using a murine FA-deficient HSPCs, we screened several inhibitors of the TGF β pathway and assessed their capacity to promote HSPCs clonogenic growth *in vitro*. These molecules included inhibitors of the TGF β RI receptor and inhibitors of the TGF β ligands themselves. Each drug promoted the growth and clonogenic potential of the FA HSPCs, thus confirming that a hyperactive TGF β pathway has a growth suppressive effect on FA hematopoiesis. Importantly, TGF β 2, but not TGF β 1 or TGF β 3, is involved in multiple developmental processes of heart and great vessels [50], and is also a positive regulator of adult HSCs [36]. Complete inhibition of the TGF β pathway might therefore have negative consequences, including unintentional stimulation of dormant tumor cells [35] or adverse side effects, such as inflammation, autoimmunity, or cardiotoxicity [50-52]. These adverse effects could have major consequences for pediatric FA patients who require novel therapies for their progressing BMF.

Using AVID200, a potent TGF β trap against TGF β 1 and β 3, with minimal activity against TGF β 2, we have performed the first preclinical studies avoiding the potential negative side effects that TGF β 2 inhibition might have. We proved that AVID200 promotes cell proliferation and/or clonogenic survival in a large number of FA primary bone marrow samples, with the strongest effect on HSPCs from patients with severe aplastic anemia and in patients with **cytogenetic** evidence of clonal chromosome abnormalities.

In our studies, mouse *Fancd2*^{-/-} and *Fancg*^{-/-} HSPCs, and the human *FANCG* deficient lymphoblast cells, were rescued from acetaldehyde toxicity when they were concomitantly treated or pre-treated *in vitro* with AVID200. AVID200 also reduced the DNA damage foci and chromosomal aberrations. A mouse *in vivo* assay confirmed that the DNA damage burden caused by pl:pC-induced physiological stress in the LT-HSC compartment [43] can be dramatically reduced when AVID200 is concomitantly administered with pl:pC treatment in mice. Importantly, here we demonstrate that genotoxicity induced by endogenous aldehyde and physiological stress can be lowered by AVID200, which might result from changes in expression of genes mediating DNA repair.

TGF β pathway is known to play a role in maintaining genomic stability by regulating the transcription of genes involved in DNA damage response [53]. Importantly, TGF β pathway hyperactivity promotes the expression of alternative error-prone DNA repair genes [54]. Accordingly, inhibition of TGF β 1 and TGF β 3 with AVID200 might modulate this transcriptional landscape. The improved survival of FA cells by AVID200 may therefore be a consequence of improved DNA repair capacity. Gene expression analysis in mouse *Fancd2*^{-/-} HSPCs and in a human *FANCG* deficient lymphoblast cells, showed

that indeed AVID200 effectively modifies the expression profile of DNA repair genes, frequently downregulating the expression of error-prone NHEJ genes.

TGF β pathway activation can promote genomic instability by downregulating RAD51 protein expression [55] or by reducing the efficiency of DNA DSB repair by downregulating the expression of various homologous recombination repair genes, such as *BLM*, *BRCA2*, *FANCF*, *NBN*, *RAD50*, *RDM1*, *WRN*, *ATM* and *ATR* [54]. The response of cells to TGF β pathway signaling, and thus the response to its inhibition, is highly context dependent [22]. Indeed, we observed differences in the subsets of DNA repair genes, either downregulated or upregulated, depending on the cell type in which the TGF β pathway is inhibited. We consistently found NHEJ genes to be downregulated in FA models upon AVID200 treatment; however, the specific genes were not the same in every system studied. For example, *Tp53bp1* (coding for 53bp1) and *Prkdc* (coding for DNA-PK) were downregulated in murine HSPCs, whereas *MAD2L2/REV7* was downregulated in the human *FANCG* deficient lymphoblast cell line. *TERF1* and *Terf1*, telomere maintenance associated genes [56] in human and mouse respectively, were genes consistently downregulated by AVID200, suggesting that AVID200 may reduce on DNA damage in FA cells by downregulation of this gene, a hypothesis that warrants further study. Although we did not explore epigenetic modifications in the regulatory regions controlling the expression of DNA repair genes, we speculate that AVID200 might modify the chromatin state of NHEJ genes or interfere with the recruitment of critical transcription factors to the promoters of these genes, opening new avenues of exploration.

Although TGF β 1 levels appear not to be high in FA, so as to have a crucial role in

downstream activation of the TGF β pathway, AVID200 has the advantage in the FA patient setting of inhibiting both TGF β 1 and TGF β 3 function while, at the same time, preserving the positive functions of TGF β 2. AVID200 is currently in phase 1 clinical trials in patients with advanced or metastatic solid tumor and its safety has been evaluated in several preclinical models. Our results open the possibility of using AVID200 as a more precise therapy for FA patients, avoiding the use of broad inhibitors of the TGF β family, which are multifunctional and highly context-dependent signaling molecules.

AUTHORSHIP CONTRIBUTIONS

AR designed the study, performed experiments and wrote the manuscript; CY, MV, JF, LAS, TP, PFG, SS, OVB and ME performed experiments; EF, BGT, AMO, AF, AS and SF provided access to clinical samples, patients' follow-up and performed clinical correlations; HM, JG and MG provided critical reagents; KP and ADD designed the study

and wrote the manuscript. ADD coordinated the project. All authors discussed the results and commented on the manuscript.

CONFLICT OF INTEREST AND DISCLOSURE

A.D. D'Andrea is a consultant/advisory board member for Lilly Oncology, Merck-EMD Serono, Intellia Therapeutics, Sierra Oncology, Cyteir Therapeutics, Third Rock Ventures, AstraZeneca, Ideaya Inc., Cedilla Therapeutics Inc., a stockholder in Ideaya Inc., Cedilla Therapeutics Inc., and Cyteir, and reports receiving commercial research grants from Lilly Oncology and Merck-EMD Serono. Other authors declare no conflicts of interest.

ACKNOWLEDGMENTS

This research was supported by grants from the U.S. National Institutes of Health (R37HL052725, P01HL048546), the Leukemia and Lymphoma Society (6237-13), and the Fanconi Anemia Research Fund (to ADD); SEP-CONACYT (243102) and PAPIIT (IA202615) to Sara Frías. We thank Forbius (Formation Biologics), Inc for providing the AVID200 used for the experiments in this study.

Table 1. FA patients included in this study

Table 1. FA patients included in this study								
Study ID	Sex	Age	FA subtype	Ethnicity/Origin	Aplastic anemia	Cytogenetic clone	Karyotype in BM	Peripheral blood T-cell mosaicism
1	F	8.2	FANCA	Mexican mestizo	No aplastic anemia	No	44,XX,t(4;13)(q34;q12.1),-22[1]/45,XX,-5[1]/44,XX,-5,-15[1]/43,XX,-6,-14,-15[1]/45,XX,-9[1]/46,XX,inv(9)(p11q12)[1]/45,XX,-10[1]/44,XX,-11,-22[1]/44,XX,-12,-20[1]/46,XX,inv(18)(p11.2q12.2)[1]/46,XX [10]	No
2	M	17.8	Unknown	Mexican mestizo	No aplastic anemia	Yes	45,XY,-16[3]/46,XY[12]	No
3	M	10.3	FANCA		No aplastic anemia	No	46,XY[20]	Yes
4	M	2.7	FANCC	Arabic	No aplastic anemia	No	46,XY[20]	Yes
5	F	3.1	FANCC	White	Mild aplastic anemia	No	46,XX[20]	No
6	F	12.0	FANCC	Arabic	Mild aplastic anemia	Yes	46,XX,del(7)(q31q36)[5]/46,XX [15]. FISH: del7q (19.5% of cells)	Yes
7	M	7.8	FANCC	Arabic	Mild aplastic anemia	No	46,XY[20]	Yes
8	M	26.5	FANCA	White	Mild aplastic anemia	Yes	46,XY,dup(12)(q15q13)[6]/46,XY[14]	No
9	M	9.2	FANCC		Mild aplastic anemia	Yes	46,XY. FISH: del13q (35.5% of cells)	No
10	F	6.9	FANCA	Mexican mestizo	Mild aplastic anemia	No	46,XX [20]	No
11	M	8.6	Unknown	White	Moderate aplastic anemia	No	46,XY[20]	No
12	F	10.9	FANCA	Mexican mestizo	Moderate aplastic anemia	No	46,XX [20]	No
13	F	15.4	Unknown	Mexican mestizo	Severe aplastic anemia	Yes	45,XX-7[10]/46,XX[10]	No
14	F	8.3	FANCG	Mexican mestizo	Severe aplastic anemia	No	46,XX [20]	No
15	F	12.0	Unknown	Mexican mestizo	Severe aplastic anemia	Unknown	No growth	No
16	M	10.2	Unknown	Mexican mestizo	Severe aplastic anemia	No	45,XY,-2[1]/45,XY,-18[1]/46,XY[18]	No
17	F	8.8	Unknown	Mexican mestizo	Severe aplastic anemia	No	46,XX [20]	No
18	M	8.2	Unknown	Mexican mestizo	Severe aplastic anemia	No	46,XY[20]	No
19	M	8.6	FANCA	Mexican mestizo	Severe aplastic anemia	No	No clone detected by FISH	No
20	M	10.1	FANCA	Mexican mestizo	Severe aplastic anemia	No	No clone detected by FISH	No
21	M	5.6	Unknown	Mexican mestizo	Severe aplastic anemia	No	No clone detected by FISH	No

FIGURE LEGENDS

Figure 1. Inhibition of the TGF β pathway promotes clonogenic growth of HSPCs from FA mice.

A) Western blots of the lysates from murine bone marrow cells. Lin⁻ cells from bone marrow of wild-type mice were cultured for 2 h in presence of TGF β 1 (5 ng/ml), TGF β 2 (5 ng/ml) or TGF β 3 (5 ng/ml) with or without AVID200. Note that two types of antibodies were used to detect the phospho-SMAD2 levels. One of the antibodies **was** used only against phospho-Smad2 (p-Smad2) whereas the other one was against both phospho-Smad2 and Smad3 (p-Smad2/3). A representative blot is shown.

B) TGF β pathway inhibitors promote colony formation of murine *Fancd2*^{-/-} HSPCs. Lin⁻ cells from wild-type (WT) or *Fancd2*^{-/-} mice were cultured for 7 days in methylcellulose medium with inhibitors of the TGF β pathway, namely, SD208 (10 μ M), 1D11 (10 μ g/mL) and AVID200 (0.2 ng/mL). Hematopoietic colonies were quantified (n=3).

p-values of 0.01 to 0.05 were considered significant (*), p-values of 0.001 to 0.01 were considered very significant (**) and p-values of <0.001 were considered extremely significant (****). **Data in (B) are represented as mean $\pm$ SEM.** See also Supplementary Figure 1.

Figure 2. Inhibition of the TGF β pathway with AVID200 rescues clonogenic defects of primary bone marrow from FA patients.

A) TGF β pathway inhibitors promote cell growth (colony formation) of primary human FA-like cells. Healthy human cord blood CD34⁺ cells were infected with two different lentivirus expressing a shRNA against the human *FANCD2* gene, thus generating FA-like cells. Human FA-like cells were then exposed to increasing concentrations of AVID200 (0.06, 0.2, 0.6, and 1.8 ng/mL) or SD208 (1 μ M), as a positive control of TGF β pathway inhibition, colony formation was assessed after 14 days of culture in methylcellulose medium (n=3).

B) Levels of free TGF β 1, TGF β 2 and TGF β 3 ligands in primary bone marrow plasma from FA patients (n=12) and healthy donors (n=5). Levels of free TGF β 2 are significantly reduced in BM plasma from FA patients, whereas levels of free TGF β 3 are significantly increased in FA patients.

C) Clonogenic growth of bone marrow progenitors isolated from FA patients (n=19) and healthy donors (n=3). Primary progenitor cells were isolated from bone marrow of 21 FA patients or 3 healthy donors and cultured in triplicates in complete methylcellulose medium with or without AVID200 (0.2 ng/mL) for 14 days and clonogenic growth was assessed for total colonies, myeloid colonies and erythroid colonies, patient 1 and 15 behaved as outliers and were removed from statistical analysis. Left panel shows raw average CFU-C numbers per sample from normal donor or FA patient. Right panel shows the fold change in colony numbers in the AVID200 treated samples after normalization with respect to the vehicle-treated control. Comparisons in both raw CFU-C numbers and fold change converted numbers were made by matching each vehicle-treated sample with its respective AVID200 treated sample per patient (matching pair).

D) Representative photomicrograph showing improved clonogenic growth of a FA bone marrow sample after AVID200 exposure *in vitro* in comparison to a bone marrow sample from a healthy donor control. Erythroid colonies are indicated in red, Myeloid colonies are indicated in yellow, multipotent colonies are indicated in blue.

E) Correlation between the degree of anemia in FA patients and response to AVID200 showing that the response to AVID200 is significantly better in the bone marrow from FA patients with severe bone marrow failure than the bone marrow from patients with mild anemia. *Left panel. Raw average CFU-C numbers per patient's sample. Right panel.* Absolute mean colony numbers were normalized to fold-change and FA patients were classified according to the severity of their aplastic anemia.

F) Correlation between the **presence of a cytogenetic clone** in FA patients and the response to AVID200 showing that patients with chromosomal clonal abnormalities, detected by **bone marrow** karyotype or FISH, responded better to AVID200 treatment *in vitro*. *Left panel. Raw average CFU-C numbers per patient's sample. Right panel.* For comparisons the absolute mean colony numbers were normalized to fold-change and FA patients were classified according to bone marrow karyotypes performed the day of progenitor cells isolation and culture.

p-values of 0.01 to 0.05 were considered significant (*), p-values of 0.001 to 0.01 were considered very significant (**) and p-values of <0.001 were considered extremely

significant (***). Data in (A) are represented as mean $\pm$ SEM, data in (B), (C), (E) and (F) are presented as boxplots. See also Supplementary Figure 2.

Figure 3. Inhibition of the TGF β pathway with AVID200 rescues genotoxicity in FA mouse models.

A) AVID200 improves the survival of mouse FA bone marrow after exposure to acetaldehyde. Lin⁻ cells from bone marrow of wild-type (WT) or *Fancd2*^{-/-} mice were pretreated with AVID200 (0.2 ng/mL) and exposed to acetaldehyde (2 mM) for 4 hrs. After washing, the cells were cultured in complete methylcellulose medium with and without AVID200 for 7 days and survival of the hematopoietic progenitors was determined by quantification of hematopoietic colonies (n=3).

B) AVID200 reduces acetaldehyde-induced DNA damage in HSPCs from bone marrow of FA mice. LSK cells from wild-type (WT) or *Fancd2*^{-/-} mice were pretreated with AVID200 (0.2 ng/mL) for 24 h and exposed to acetaldehyde (2 mM) for 4 h. After washing, the cells were allowed to recover for 48 h in StemSpan Medium supplemented with cytokines TPO, SCF, Flt3 ligand and L-Glutamine. The cells were then analyzed for γ H2AX foci by immunofluorescence. 100 cells were counted per condition (n=3).

C) AVID200 modifies the gene expression profile of DNA repair related genes in mouse LSK cells. LSK cells from wild-type (WT) or *Fancd2*^{-/-} mice were exposed to AVID200 (0.2 ng/mL) for 48 hrs and gene expression profile was analyzed. Note the downregulation of *Trp53bp1*, *Prkdc* and *Trp53*, in cells from *Fancd2*^{-/-} mice (n=3).

D) AVID200 prevents polyinosinic:polycytidylic acid (pl:pC)-induced DNA damage in LT-HSCs from bone marrow of FA mice *in vivo*. Wild-type (WT) and *Fancd2*^{-/-} mice (n=3 mice per group) were co-injected with water, pl:pC (5 mg/kg), AVID200 (5 mg/kg) or a combination of both. LT-HSCs were isolated and DNA damage was assessed by immunofluorescence staining of γ H2AX foci, *left panel* shows the amount of γ H2AX foci per cell 48 h after injection, whereas *right panel* shows the amount of γ H2AX foci per cell after 30 days of 2 injections per week (n=5 mice per group).

(E) Representative pictures of γ H2AX foci in LT-HSC are shown. At least 50 cells from each group were scored for γ H2AX foci.

p-values of 0.01 to 0.05 were considered significant (*), p-values of 0.001 to 0.01 were considered very significant (**) and p-values of <0.001 were considered extremely significant (***, ****). Data in (A) and (B) are represented as mean $\pm$ SEM, data in (C) are presented as scatter plot, data in (D) are presented as boxplot. See also Supplementary Figure 3.

Figure 4. Inhibition of the TGF β pathway with AVID200 rescues genotoxicity in FA-derived human cell lines.

A) AVID200 improves the survival of *FANCG*-deficient human FA lymphoblast cells in presence of acetaldehyde. *FANCG*-deficient parental cells (EUFA316+EV) and *FANCG*-corrected cells (EUFA316+FANCG) were exposed to graded concentration of

acetaldehyde and AVID200 (0.2 ng/mL) for 6 days and survival was determined by CellTiter Glo reagent (n=12 per condition).

B) AVID200 pretreatment reduces the frequency of Mitomycin C (MMC)-induced chromosomal aberrations in *FANCG*-deficient cells. EUFA316+EV cells and EUFA316+*FANCG* cells were pre-treated with AVID200 before exposure to MMC and metaphase spreads of the chromosomes were scored for chromosomal aberrations. Quantification of the MMC-induced chromosomal aberrations is shown in the left panel (n=3). A representative metaphase from the EUFA316+EV cell line treated with MMC is shown in the right panel, red arrow indicates a radial figure.

C) Volcano plot showing DNA repair-related differentially expressed genes of the *FANCG*-deficient cell line (EUFA316+EV) relative to the *FANCG*-corrected cell line (EUFA316+*FANCG*). The log fold change in the EUFA316+EV cell line versus the EUFA316+G cell line is represented on the x-axis. The y-axis shows the Log₁₀ of the *p* value. Downregulated genes with a *p* value of 0.05 are indicated in blue, whereas upregulated genes with a *p* value of 0.05 are indicated in red (n=3).

D) Volcano plot showing DNA repair-related differentially expressed genes of the *FANCG*-deficient cell line (EUFA316+EV) after 24 h exposure to AVID200 (0.2 ng/mL). The log fold change in the EUFA316+EV + AVID200 cell line versus the untreated cell line is represented on the x-axis. The y-axis shows the Log₁₀ of the *p* value.

Downregulated genes with a *p* value of 0.05 are indicated in blue, whereas upregulated genes with a *p* value of 0.05 are indicated in red (n=3).

p-values of 0.01 to 0.05 were considered significant (*), *p*-values of 0.001 to 0.01 were considered very significant (**) and *p*-values of <0.001 were considered extremely significant (***, ****). Data in (A) are represented as mean $\pm$ SEM, data in (B) are presented as boxplot, data in (C) and (D) are presented as volcano plots. See also Supplementary Figure 4.

Supplementary Figure 1. Related to Figure 1. AVID200 inhibits TGF β pathway signaling in primary mouse bone marrow cells.

A) Reduced activation of the TGF β pathway by AVID200 in mouse bone marrow progenitors. Murine bone marrow Lin⁻ progenitors were exposed to TGF β 1 (5 ng/mL) along with AVID200 (0.2 ng/mL) or 1D11 (10 μ g/mL) as a positive control and the cells were stained with phospho-SMAD2/3 antibody. Phospho-SMAD2/3 staining was then detected by flow cytometry. Representative FACS plots for staining in wild-type (WT) cells are shown.

B) Quantitation of the staining intensity as mean fluorescence value (MFI) in the Lin⁻ cells from WT and *Fancd2*^{-/-} mice is shown in panel B.

C) Raw total colony numbers from colony formation assay shown in Figure 1B. Lin⁻ cells from wild-type (WT) or *Fancd2*^{-/-} mice were cultured for 7 days in methylcellulose medium

with inhibitors of the TGF β pathway, namely, SD208 (10 μ M), 1D11 (10 μ g/mL) and AVID200 (0.2 ng/mL). Hematopoietic colonies were quantified (n=3).

D) Cell numbers after solubilization of hematopoietic colonies in methylcellulose medium. Lin⁻ cells from WT and *Fancd2*^{-/-} mice were cultured in methylcellulose medium for 7 days in the presence or absence of AVID200 (0.2 ng/mL), colonies quantified, and methylcellulose was solubilized with PBS. The number of cells per well was quantified and plotted (n=3).

p-values of 0.01 to 0.05 were considered significant (*) and p-values of 0.001 to 0.01 were considered very significant (**). Data in (C) are represented as mean $\pm$ SEM, data in (D) are presented as boxplots.

Supplementary Figure 2. Related to Figure 2. AVID200 enhances clonogenic growth of myeloid and erythroid progenitors from bone marrow of FA patients.

A) *FANCD2* gene expression analysis by Real time PCR showing the knockdown efficiency of sh1 *FANCD2* and sh3 *FANCD2* in human cord blood CD34⁺ cells. Error bars represent S.E.M. n=3.

B) Raw total colony numbers from colony formation assay for primary human FA-like CD34⁺ cells shown in Figure 2A. Human FA-like CD34⁺ cells were then exposed to increasing concentrations of AVID200 (0.06, 0.2, 0.6, and 1.8 ng/mL) or SD208 (1 μ M),

as a positive control of TGF β pathway inhibition, colony formation was assessed after 14 days of culture in methylcellulose medium (n=3).

C) Cell numbers after solubilization of hematopoietic colonies in methylcellulose medium. FA-like CD34⁺ cells were cultured in methylcellulose medium for 14 days in the presence or absence of AVID220 (0.2 ng/mL), colonies quantified, and methylcellulose was solubilized with PBS. The number of cells per well was quantified and plotted (n=3).

D) Total TGF β 1, TGF β 2 and TGF β 3 ligand levels in the bone marrow plasma of FA patients (n=12) and normal donors (n=5). Levels of total TGF β 1 and TGF β 2 are significantly reduced in BM plasma from FA patients, whereas levels of total TGF β 3 are significantly increased in FA patients.

E) AVID200 promotes the proliferation of bone marrow progenitors from FA patients. Progenitor cells isolated from bone marrow of 9 FA patients and 3 healthy donors were cultured in StemSpan medium with TPO (100 ng/ml) (AF-300-18, Peprotech), Flt-3 (100 ng/ml) (AF-300-19, Peprotech), SCF (100 ng/ml) (AF-300-07, Peprotech) and IL-6 (20 ng/ml) (AF-200-06, Peprotech) for 7 days and live cells were counted. Note that healthy bone marrow cells did not respond or had a poor response to AVID200 treatment.

sm= single measurement in samples with very few progenitors. *ns*=non-significant.

F) Primary progenitor cells isolated from bone marrow of 20 FA patients or 3 healthy donors were cultured in triplicates in complete methylcellulose medium with or without

AVID200 (0.2 ng/mL) for 14 days. Total number of hematopoietic colonies (total CFU) including myeloid colonies as well as erythroid colonies are shown per sample.

G) Myeloid CFU-C production of bone marrow from individual FA patients or normal donor in response to AVID200 after 14 days of culture in complete methylcellulose medium with or without AVID200 (0.2 ng/mL).

H) Erythroid CFU-C production of bone marrow from individual FA patient or normal donor in response to AVID200 after 14 days of culture in complete methylcellulose medium with or without AVID200 (0.2 ng/mL).

p-values of 0.01 to 0.05 were considered significant (*), p-values of 0.001 to 0.01 were considered very significant (**) and p-values of <0.001 were considered extremely significant (***). Data in (A), (E), (F), (G) and (H) are presented as bar graphs, data in (B) are presented as mean $\pm$ SEM, data in (D) are presented as boxplots.

Supplementary Figure 3. Related to Figure 3. AVID200 rescues genotoxicity in bone marrow progenitors from FA mice.

A) Lin⁻ cells from the bone marrow of wild-type or *Fancg*^{-/-} mice were pretreated with AVID200 (0.2 ng/mL) and exposed to acetaldehyde (2 mM) for 4 h. The survival of cells was determined by clonogenic assay after culturing them in methylcellulose medium for 7 days (n=3).

B) LSK cells from the bone marrow of wild-type or *Fancd2*^{-/-} mice were pretreated with AVID200 (0.2 ng/mL), exposed to acetaldehyde (2 mM) for 4 h and then allowed to recover for 7 days in StemSpan medium enriched with cytokines SCF, Flt3 ligand, TPO and L-Glutamine. Survival of the cells was determined by counting the number of live cells after 7 days of culture (n=3).

C) AVID200 reduces the amount of acetaldehyde-induced unrepaired single stranded DNA in bone marrow cells. LSK cells from bone marrow of wild-type (WT) or *Fancd2*^{-/-} mice were exposed to acetaldehyde and BrdU along with AVID200 as indicated in the schematic in panel C and the amount of unrepaired single stranded DNA was measured by immunofluorescence as BrdU foci. Note that exposure to acetaldehyde increases the number of unrepaired single stranded DNA, measured as BrdU foci, in *Fancd2*^{-/-} LSK cells. AVID200 reduces the amount of unrepaired single stranded DNA, as demonstrated by the reduction of BrdU foci.

C) Representative images of BrdU foci in LSK cells are shown in panel D. At least 30 cells were counted for BrdU foci.

E) AVID200 reduces pl:pC-induced DNA damage in LT-HSCs of *Fancd2*^{-/-} mice. WT or *Fancd2*^{-/-} mice were co-injected with pl:pC (5 mg/kg) and AVID200 (5 mg/kg), LT-HSCs were isolated after 48 h of the treatment and comet assay was performed to analyze DNA damage. Quantitation of the Olive tail moment in the LT-HSC is shown in panel E.

F) Representative images of the pl:pC-induced alkaline comets in LT-HSCs are shown in panel F.

p-values of 0.01 to 0.05 were considered significant (*), p-values of 0.001 to 0.01 were considered very significant (**) and p-values of <0.001 were considered extremely significant (***, ****). Data in (A) and (B) are presented as mean $\pm$ SEM, data in (C) and (E) are presented as boxplots.

Supplementary Figure 4. Related to Figure 4. AVID200 reduces the acetaldehyde-induced chromosomal aberrations in *FANCG* deficient lymphoblast cells.

A) EUFA316+EV cells and EUFA316+*FANCG* cells were pre-treated with AVID200 before exposure to acetaldehyde. The cells were then allowed to recover, and metaphase spreads of chromosomes were scored for chromosomal abnormalities (n=3). Data are presented as bar graphs.

REFERENCES

1. Shimamura, A. and B.P. Alter, *Pathophysiology and management of inherited bone marrow failure syndromes*. Blood Rev, 2010. **24**(3): p. 101-22.
2. Ceccaldi, R., P. Sarangi, and A.D. D'Andrea, *The Fanconi anaemia pathway: new players and new functions*. Nat Rev Mol Cell Biol, 2016. **17**(6): p. 337-49.

3. Tischkowitz, M. and I. Dokal, *Fanconi anaemia and leukaemia—clinical and molecular aspects*. Br. J. Haematol, 2004. **126**(2): p. 176-191.
4. Ceccaldi, R., et al., *Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells*. Cell Stem Cell, 2012. **11**(1): p. 36-49.
5. Garaycochea, J.I. and K.J. Patel, *Why does the bone marrow fail in Fanconi anemia?* Blood, 2014. **123**(1): p. 26-34.
6. Savage, S.A. and M.F. Walsh, *Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia*. Hematol Oncol Clin North Am, 2018. **32**(4): p. 657-668.
7. Wegman-Ostrosky, T. and S.A. Savage, *The genomics of inherited bone marrow failure: from mechanism to the clinic*. Br J Haematol, 2017. **177**(4): p. 526-542.
8. Knies, K., et al., *Biallelic mutations in the ubiquitin ligase RFW3 cause Fanconi anemia*. J Clin Invest, 2017. **127**(8): p. 3013-3027.
9. Rodriguez, A. and A. D'Andrea, *Fanconi anemia pathway*. Curr Biol, 2017. **27**(18): p. R986-R988.
10. Clauson, C., O.D. Scharer, and L. Niedernhofer, *Advances in understanding the complex mechanisms of DNA interstrand cross-link repair*. Cold Spring Harb Perspect Biol, 2013. **5**(10): p. a012732.
11. Kottmann, M.C. and A. Smogorzewska, *Fanconi anaemia and the repair of Watson and Crick DNA crosslinks*. Nature, 2013. **493**(7432): p. 356-63.
12. D'Andrea, A.D., *Susceptibility pathways in Fanconi's anemia and breast cancer*. N Engl J Med, 2010. **362**(20): p. 1909-19.
13. Zhang, H., et al., *TGF-beta Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia*. Cell Stem Cell, 2016. **18**(5): p. 668-81.
14. Millan, F.A., et al., *Embryonic gene expression patterns of TGF beta 1, beta 2 and beta 3 suggest different developmental functions in vivo*. Development, 1991. **111**(1): p. 131-43.
15. Worthington, J.J., J.E. Klementowicz, and M.A. Travis, *TGFbeta: a sleeping giant awoken by integrins*. Trends Biochem Sci, 2011. **36**(1): p. 47-54.
16. Khalil, N., et al., *TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study*. Am J Respir Cell Mol Biol, 1996. **14**(2): p. 131-8.
17. Willis, B.C., et al., *Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis*. Am J Pathol, 2005. **166**(5): p. 1321-32.
18. Agarwal, A., et al., *Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-beta*. Stem Cell Investig, 2016. **3**: p. 5.
19. Vannucchi, A.M., et al., *A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis*. Blood, 2005. **105**(9): p. 3493-501.
20. Bachegowda, L., et al., *Signal transduction inhibitors in treatment of myelodysplastic syndromes*. J Hematol Oncol, 2013. **6**: p. 50.
21. Gong, Y., et al., *Megakaryocyte-derived excessive transforming growth factor beta1 inhibits proliferation of normal hematopoietic stem cells in acute myeloid leukemia*. Exp Hematol, 2018. **60**: p. 40-46 e2.
22. David, C.J. and J. Massague, *Contextual determinants of TGFbeta action in development, immunity and cancer*. Nat Rev Mol Cell Biol, 2018. **19**(7): p. 419-435.

23. Anido, J., et al., *TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma*. *Cancer Cell*, 2010. **18**(6): p. 655-68.
24. Naka, K., et al., *TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia*. *Nature*, 2010. **463**(7281): p. 676-80.
25. Xie, F., et al., *FAF1 phosphorylation by AKT accumulates TGF-beta type II receptor and drives breast cancer metastasis*. *Nat Commun*, 2017. **8**: p. 15021.
26. Bogdahn, U., et al., *Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study*. *Neuro Oncol*, 2011. **13**(1): p. 132-42.
27. Ikeda, M., et al., *Phase Ib study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer*. *Cancer Chemother Pharmacol*, 2017. **79**(6): p. 1169-1177.
28. Herbertz, S., et al., *Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway*. *Drug Des Devel Ther*, 2015. **9**: p. 4479-99.
29. Komrokji, R., et al., *Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial*. *Lancet Haematol*, 2018. **5**(2): p. e63-e72.
30. Habashi, J.P., et al., *Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome*. *Science*, 2006. **312**(5770): p. 117-21.
31. Bialkowski, L., et al., *Immune checkpoint blockade combined with IL-6 and TGF-beta inhibition improves the therapeutic outcome of mRNA-based immunotherapy*. *Int J Cancer*, 2018. **143**(3): p. 686-698.
32. Mariathasan, S., et al., *TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells*. *Nature*, 2018. **554**(7693): p. 544-548.
33. Strauss, J., et al., *Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFbeta, in Advanced Solid Tumors*. *Clin Cancer Res*, 2018. **24**(6): p. 1287-1295.
34. Gao, X., et al., *TGF-beta inhibitors stimulate red blood cell production by enhancing self-renewal of BFU-E erythroid progenitors*. *Blood*, 2016. **128**(23): p. 2637-2641.
35. Bragado, P., et al., *TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling*. *Nat Cell Biol*, 2013. **15**(11): p. 1351-61.
36. Langer, J.C., et al., *Quantitative trait analysis reveals transforming growth factor-beta2 as a positive regulator of early hematopoietic progenitor and stem cell function*. *J Exp Med*, 2004. **199**(1): p. 5-14.
37. Thwaites M, K.J., Tremblay, G, O'Connor-McCourt, M, *AVID200: A Novel TGF-β Inhibitor for the Treatment of Anemia Associated with Myelodysplastic Syndromes*. *Blood* 2017. **130**(Suppl 1): p. 2532.
38. Joyce, C.E., et al., *TGFbeta signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome*. *J Clin Invest*, 2019. **129**(9): p. 3821-3826.
39. Garaycochea, J.I., et al., *Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function*. *Nature*, 2012. **489**(7417): p. 571-5.
40. Garaycochea, J.I., et al., *Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells*. *Nature*, 2018. **553**(7687): p. 171-177.

41. Adamo, A., et al., *Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia*. Mol Cell, 2010. **39**(1): p. 25-35.
42. Pace, P., et al., *Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway*. Science, 2010. **329**(5988): p. 219-23.
43. Walter, D., et al., *Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells*. Nature, 2015. **520**(7548): p. 549-52.
44. Ceccaldi, R., et al., *Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair*. Nature, 2015. **518**(7538): p. 258-62.
45. Sallmyr, A. and A.E. Tomkinson, *Repair of DNA double-strand breaks by mammalian alternative end-joining pathways*. J Biol Chem, 2018. **293**(27): p. 10536-10546.
46. Ghezraoui, H., et al., *53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ*. Nature, 2018. **560**(7716): p. 122-127.
47. Noordermeer, S.M., et al., *The shieldin complex mediates 53BP1-dependent DNA repair*. Nature, 2018. **560**(7716): p. 117-121.
48. Dev, H., et al., *Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells*. Nat Cell Biol, 2018. **20**(8): p. 954-965.
49. Akhurst, R.J. and A. Hata, *Targeting the TGFbeta signalling pathway in disease*. Nat Rev Drug Discov, 2012. **11**(10): p. 790-811.
50. Bartram, U., et al., *Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice*. Circulation, 2001. **103**(22): p. 2745-52.
51. Shull, M.M., et al., *Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease*. Nature, 1992. **359**(6397): p. 693-9.
52. Anderton, M.J., et al., *Induction of heart valve lesions by small-molecule ALK5 inhibitors*. Toxicol Pathol, 2011. **39**(6): p. 916-24.
53. Barcellos-Hoff, M.H. and F.A. Cucinotta, *New tricks for an old fox: impact of TGFbeta on the DNA damage response and genomic stability*. Sci Signal, 2014. **7**(341): p. re5.
54. Pal, D., et al., *TGF-beta reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells*. Elife, 2017. **6**.
55. Kanamoto, T., et al., *Functional proteomics of transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFbeta1-dependent regulation of DNA repair*. EMBO J, 2002. **21**(5): p. 1219-30.
56. Hockemeyer, D. and K. Collins, *Control of telomerase action at human telomeres*. Nat Struct Mol Biol, 2015. **22**(11): p. 848-52.